SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 31.80-0.1%Nov 21 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert K. who wrote (4932)11/29/1997 1:29:00 PM
From: aknahow  Read Replies (2) of 17367
 
Bob, thanks. Wonder if this will generate a response from Giroir or additional details. I thought XOMA claimed the non mortality outcomes were also better. Wonder about the historical incidence of amputations in meningococcemia.

Believe this response by Duncan (?) proves the need for XOMA to provide as great amount of info as possible to keep shareholders from being blindsided.

Also demonstrates that it might have been good to involve the Aussies in P III for more than jut inclusion of Southern Hemisphere.

P III seould be near 135 level. We know BPI does not make patients sicker. It may not cure them all but it would seem to be having some positve effect. And DSMB should be meeting soon, (my guess).

Negative side of letter is that it gives more info than the original abstract and that fence siters now have a real reason to wait before committing to XOMA. Even so people like Sturza analyst were reading the whole origal article not just the abstract so they were aware of the 7 amputations. If BPI works really well the success will be even more spectacular given the doubts. Since P III trial has not been halted I do not believe results are much more favorabale than expected. But do think they probably are positive.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News